A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Inclusion Criteria:

• Open to participants from STAR-0215-201 (NCT05695248) who have met one of thefollowing conditions:

• Completed STAR-0215-201 (follow up through 6 months after their last dose);

• Eligible for STAR-0215-201 and entered the Run-In period but did not qualifyfor the Treatment Period because they did not meet the criterion for theminimum number of HAE attacks;

• Eligible for STAR-0215-201 and entered the Run-In period but did not completeit for reasons other than not meeting the criterion for the minimum number ofHAE attacks (eligibility requires consultation with the Medical Monitor); or

• Discontinued STAR-0215-201 (for reasons other than safety) after havingcompleted at least 84 days of trial follow-up since their last dose ofSTAR-0215 (eligibility requires consultation with the Medical Monitor).

• Open to participants who are STAR-0215 naïve and were not enrolled in STAR-0215-201 (NCT05695248), have a documented diagnosis of HAE (Type 1 or Type 2).

Exclusion Criteria:

• Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1inhibitor deficiency, HAE with normal C1-esterase inhibitor protein (also known asHAE Type III), idiopathic angioedema, or angioedema associated with urticaria.

• Any exposure to angiotensin-converting enzyme inhibitors or any estrogen-containingmedications with systemic absorption (such as hormonal contraceptives or hormonereplacement therapy) within 28 days prior to Screening

• Any exposure to androgens (for example, stanozolol, danazol, oxandrolone,methyltestosterone, testosterone) within 7 days prior to Screening.

• Use of therapies prescribed for the prevention of HAE attacks prior to Screening:

• lanadelumab within 90 days

• berotralstat within 21 days

• all other prophylactic therapies, discuss with the Medical Monitor

Note: Other inclusion and exclusion criteria may apply.